Search

Displaying results 1051 - 1060 of 7554 in total
  1. Drug

    Baloxavir marboxil

    go.drugbank.com/drugs/DB13997
    ApprovedInvestigational

    [L4779] It was also approved by the European Commission on January 7, 2021.[L45241] … [A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018.

  2. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective. … [L34440] Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was

  3. Drug

    Ancrod

    go.drugbank.com/drugs/DB05099
    ApprovedWithdrawn

    Currently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S. … FDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood

  4. Drug

    Octreotide

    go.drugbank.com/drugs/DB00104
    ApprovedInvestigational

    This drug was developed by Chiasma Inc.[L14495,L14507,L14528] … [L14513] In the past, octreotide has been administered solely by injection.

  5. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide … This decision was supported by findings from the phase 3 SORAYA trial (NCT04296890).[L43967,L43972] It was subsequently granted full approval in March 2024.

  6. Drug

    Cefoxitin

    go.drugbank.com/drugs/DB01331
    ApprovedInvestigational

    It is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>.

  7. Drug

    Sulbactam

    go.drugbank.com/drugs/DB09324
    ApprovedInvestigational

    [L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296]

  8. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high

  9. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. … It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Follitropin

    go.drugbank.com/drugs/DB00066
    ApprovedInvestigational

    Further, the ogliosaccharide side chains are very similar, but not completely identical to that of natural FSH. However, these small differences do not affect the bioactivity compared to natural FSH. … However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but